ELAN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.09B

+7.22%

0.113

-19.43%

1.28B

+7.25%

0.352

-4.99%

1.31B

+5.77%

0.299

+15.16%

Estimates Revision

The market is revising Upward the revenue expectations for Elanco Animal Health Incorporated (ELAN) for FY2025, with the revenue forecasts being adjusted by 1.44% over the past three months. During the same period, the stock price has changed by 18.78%.

Revenue Estimates for FY2025

Revise Upward

+1.44%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+4.25%

In Past 3 Month

Stock Price

Go Up

+18.78%

In Past 3 Month

10 Analyst Rating

Wall Street analysts forecast ELAN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELAN is 25.13 USD with a low forecast of 23.00 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

23.00

Averages

25.13

High

27.00

Current: 0.000

Low

23.00

Averages

25.13

High

27.00

Morgan Stanley

Equal Weight

maintain

$18 -> $22

2025-12-18

Reason

Morgan Stanley

Price Target

$18 -> $22

2025-12-18

maintain

Equal Weight

Reason

Morgan Stanley raised the firm's price target on Elanco to $22 from $18 and keeps an Equal Weight rating on the shares. For healthcare technology and providers, the firm sees an "attractive backdrop for alpha-generation opportunities" in 2026, the analyst tells investors. Meanwhile, managed care stocks have underperformed in 2025 and are facing "another year of unprecedented policy, reimbursement, and utilization headwinds," the analyst added in a year-ahead outlook note for the Healthcare Services group.

Barclays

Overweight

initiated

$30

2025-12-08

Reason

Barclays

Price Target

$30

2025-12-08

initiated

Overweight

Reason

Barclays initiated coverage of Elanco with an Overweight rating and $30 price target. The firm rolled out coverage on the specialty pharmaceuticals industry with a neutral view, saying investor sentiment is improving as companies shift focus to innovation, margin expansion and de-leveraging. The group's pricing headwinds are easing while debt leverage is coming down, the analyst tells investors in a research note. Barclays sees "plenty of opportunity" as the sector "remains in a transition phase."

KeyBanc

initiated

$27

2025-11-20

Reason

KeyBanc

Price Target

$27

2025-11-20

initiated

Reason

KeyBanc initiated coverage of Elanco with an Overweight rating and $27 price target.

KeyBanc

Overweight

initiated

$27

2025-11-20

Reason

KeyBanc

Price Target

$27

2025-11-20

initiated

Overweight

Reason

KeyBanc initiated coverage of Elanco with an Overweight rating and $27 price target. The firm expects success of the company's recent product launches to boost revenue growth and expand margins, while acknowledging challenges in displacing incumbent treatments, the analyst tells investors in a research note. KeyBanc adds that it sees a significant reduction in Elanco's leverage and looks to further improvement from increasing cash flows.

Piper Sandler

David Westenberg

Neutral

upgrade

$18 -> $24

2025-11-10

Reason

Piper Sandler

David Westenberg

Price Target

$18 -> $24

2025-11-10

upgrade

Neutral

Reason

Piper Sandler analyst David Westenberg raised the firm's price target on Elanco to $24 from $18 following quarterly results. The firm keeps a Neutral rating on the shares.

UBS

Andrea Alfonso

Buy

maintain

$25 -> $27

2025-11-06

Reason

UBS

Andrea Alfonso

Price Target

$25 -> $27

2025-11-06

maintain

Buy

Reason

UBS analyst Andrea Alfonso raised the firm's price target on Elanco to $27 from $25 and keeps a Buy rating on the shares. While there was plenty to like about the Q3 report, expectations are "fairly" lofty, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Elanco Animal Health Inc (ELAN.N) is 23.48, compared to its 5-year average forward P/E of 19.21. For a more detailed relative valuation and DCF analysis to assess Elanco Animal Health Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

19.21

Current PE

23.48

Overvalued PE

25.62

Undervalued PE

12.81

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

14.23

Current EV/EBITDA

15.52

Overvalued EV/EBITDA

17.33

Undervalued EV/EBITDA

11.13

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.95

Current PS

2.29

Overvalued PS

2.72

Undervalued PS

1.19

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ELAN News & Events

Events Timeline

No data

News

5.0

01-01NASDAQ.COM

Elanco Receives USDA Approval for Befrena, New Canine Dermatitis Treatment

5.0

2025-12-31PRnewswire

Elanco Receives USDA Approval for New Canine Dermatology Drug Befrena

5.0

2025-12-31Newsfilter

Elanco Secures USDA Approval for Befrena, Targeting $1.3 Billion Canine Dermatology Market

People Also Watch

Frequently Asked Questions

What is Elanco Animal Health Inc (ELAN) stock price today?

The current price of ELAN is 23.47 USD — it has increased 0.99 % in the last trading day.

What is Elanco Animal Health Inc (ELAN)'s business?

Elanco Animal Health Incorporated is an animal health company delivering products and services to prevent and treat disease in farm animals and pets. The Company's product portfolio is sold in more than 90 countries and serves animals across many species, primarily dogs and cats (collectively, pet health) and cattle, poultry, swine, and sheep (collectively, farm animal). It has a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals. The Company's global pet health portfolio is focused on parasiticides, vaccines and therapeutics. Its pet health products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its farm animal products include AviPro, Baytril, Catosal, Denagard, Experior, Hemicell, Maxiban/Monteban, Pulmotil, Rumensin, and Surmax. Its customers include consultants, veterinarians, farm animal producers and resellers.

What is the price predicton of ELAN Stock?

What is Elanco Animal Health Inc (ELAN)'s revenue for the last quarter?

Elanco Animal Health Inc revenue for the last quarter amounts to 1.14B USD, increased 10.39 % YoY.

What is Elanco Animal Health Inc (ELAN)'s earnings per share (EPS) for the last quarter?

Elanco Animal Health Inc. EPS for the last quarter amounts to -0.07 USD, decreased -109.59 % YoY.

What changes have occurred in the market's expectations for Elanco Animal Health Inc (ELAN)'s fundamentals?

How many employees does Elanco Animal Health Inc (ELAN). have?

Elanco Animal Health Inc (ELAN) has 9000 emplpoyees as of January 10 2026.

What is Elanco Animal Health Inc (ELAN) market cap?

Today ELAN has the market capitalization of 11.66B USD.